Adamas Pharmaceuticals is a technology company.
Adamas Pharmaceuticals is a technology company.
Adamas Pharmaceuticals has raised $61.0M across 2 funding rounds.
Adamas Pharmaceuticals has raised $61.0M in total across 2 funding rounds.
Adamas Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing therapeutics for chronic neurological disorders, leveraging expertise in time-dependent biology to create medicines that match disease patterns for improved patient outcomes.[1][2] Its lead product, GOCOVRI (amantadine extended-release capsules), is the first and only FDA-approved treatment for dyskinesia in Parkinson's disease patients on levodopa therapy, addressing a key unmet need in symptom management.[1][2] The company serves patients with conditions like Parkinson's, multiple sclerosis, and epilepsy through its pipeline, including ADS-5102 for MS walking impairment and ADS-4101 (modified-release lacosamide) for partial-onset seizures, while also partnering on products like Namzaric for Alzheimer's dementia.[1][2] This positions Adamas to reduce the burden on patients, caregivers, and society by innovating in neurologic treatments, building on commercial momentum from GOCOVRI's launch.[1]
Adamas Pharmaceuticals was founded in 2000, initially aiming to deliver lasting relief for central nervous system disorders through targeted drug development.[2] The company's backstory centers on its pioneering application of time-dependent biology—mapping how disease activity fluctuates over time to design drugs with matching therapeutic profiles—emerging from a need to improve outcomes in chronic neurologic conditions where standard treatments fall short.[1] Key early traction came from partnerships, such as with Forest Laboratories (now Allergan) for Namzaric, and pivotal FDA approval of GOCOVRI, marking its first commercial product and validating its approach in Parkinson's dyskinesia.[1][2] This evolution from research-focused origins to a pipeline-driven specialty pharma player highlights founders' vision for durable clinical effects in underserved areas.[1]
Adamas stands out in the neurology space through these key strengths:
Adamas rides the wave of precision neurology, where understanding circadian and time-based disease dynamics drives next-generation therapies amid rising demand for chronic disorder management in aging populations.[1] Timing aligns with expanding markets for Parkinson's (affecting millions globally) and related conditions, fueled by advances in extended-release tech and biologic insights that traditional pharma overlooks.[1][2] Favorable forces include FDA incentives for orphan neurologic indications and partnerships accelerating commercialization, positioning Adamas to influence ecosystem shifts toward biology-matched drugs over one-size-fits-all approaches.[1][2] By pioneering in dyskinesia and pipeline expansions, it contributes to broader innovation in CNS therapeutics, bridging biotech research with real-world patient relief.
Adamas is poised for pipeline milestones, with potential approvals for ADS-5102 and ADS-4101 expanding beyond GOCOVRI into MS and epilepsy markets, amplifying revenue from its Parkinson's foothold.[1][2] Trends like AI-enhanced drug modeling and personalized neurology will shape its path, enabling faster iterations on time-dependent therapies amid growing CNS prevalence. Its influence may evolve from niche innovator to key player in chronic neuro portfolios, especially via strategic alliances—watch for Phase 3 data and partnerships to drive sustained growth, redefining treatment paradigms just as GOCOVRI did for dyskinesia.[1][2]
Adamas Pharmaceuticals has raised $61.0M in total across 2 funding rounds.
Adamas Pharmaceuticals's investors include Wildcat Ventures.
Adamas Pharmaceuticals has raised $61.0M across 2 funding rounds. Most recently, it raised $40.0M Series D in August 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2009 | $40.0M Series D | Wildcat Ventures | |
| Apr 1, 2005 | $21.0M Series B | Wildcat Ventures |